Belsomra (Suvorexant)

Belsomra (suvorexant) is a prescription sleep medicine for adults with insomnia characterised by difficulty falling asleep and/or staying asleep. The usual dose is 10 mg taken once per night within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of waking; the maximum dose is 20 mg once daily.

Suvorexant blocks the binding of the wake-promoting neuropeptides orexin A and orexin B to their receptors (OX1R and OX2R). By turning down this wake signal, it helps people fall asleep and stay asleep, rather than sedating the brain broadly.

• Belsomra can cause next-day drowsiness and impaired alertness; patients taking 20 mg should not drive or do activities requiring full alertness the next day.
• It is contraindicated in narcolepsy. Sleep paralysis, hallucinations around sleep onset and cataplexy-like symptoms can occur.
• Complex sleep behaviours (such as sleep-driving), worsening depression or suicidal thoughts should be reported to a doctor right away.
• Alcohol and other CNS depressants increase the risk of side effects. Suvorexant is a Schedule IV controlled substance in the US.

Documents required for Belsomra

Patients and hospitals can import Belsomra on a named-patient basis. Please keep these ready:

• A valid prescription from a registered psychiatrist, neurologist or sleep specialist
• Clinical assessment confirming chronic insomnia
• Patient ID proof issued by the Government of India

Is Belsomra available in India?

Belsomra is an imported medicine and is not readily available through regular pharmacies in India. It can still be accessed legally on a named-patient basis, subject to Indian import regulations.

When will my order be confirmed?

We confirm the order after the prescription has been checked and verified.

Indian Pharma Network imports Belsomra on request for patients, treating doctors and hospitals, using authorised supply channels only.

Contact us at +91-9310090915 or info@indianpharmanetwork.in for a quote and lead time for Belsomra in India.

Global Approval Status:

• Japan: Approved in 2014.
• United States: FDA-approved in August 2014 for insomnia.

What is Belsomra used for?

Belsomra (suvorexant) is an orexin receptor antagonist used for insomnia (difficulty falling asleep and/or staying asleep).

Who manufactures Belsomra?

Belsomra is from Merck & Co. (MSD).

How does Belsomra work?

Suvorexant blocks the binding of the wake-promoting neuropeptides orexin A and orexin B to their receptors (OX1R and OX2R).

Is Belsomra a sleeping pill like benzodiazepines?

No. It works differently, by blocking orexin (a wake-promoting signal) rather than acting on GABA receptors like benzodiazepines.

Is Belsomra approved by the US FDA?

Yes. Belsomra is FDA-approved for insomnia characterised by difficulty with sleep onset and/or sleep maintenance.